<?xml version="1.0" encoding="UTF-8"?>
<p id="p0135">Influenza viruses are enveloped RNA viruses which can cause morbidity or even mortality in humans by seasonal or pandemic infections. Annually, influenza epidemics lead to 200â€“500,000 fatal cases globally (
 <xref rid="bib3" ref-type="bibr">Courtin et al., 2017</xref>). Currently, therapeutic strategies to lower the mortality rates mainly rely on vaccines and chemical drugs. But usage of vaccines has been often challenged by frequent mutation of the antigen and narrow spectrum (
 <xref rid="bib23" ref-type="bibr">Tao et al., 2017</xref>; 
 <xref rid="bib30" ref-type="bibr">Zarubaev et al., 2015</xref>). On the other side, viral resistance and adverse effects restrict the clinic application of currently available anti-influenza virus drugs including neuraminidase inhibitors, M2 channel blockers and RNA synthesis inhibitors (
 <xref rid="bib6" ref-type="bibr">Hayden and De Jong, 2011</xref>; 
 <xref rid="bib21" ref-type="bibr">Samson et al., 2013</xref>; 
 <xref rid="bib2" ref-type="bibr">Correia et al., 2015</xref>). Hence, alternative drugs with low toxicity, broad spectrum and less resistance remain to be developed.
</p>
